A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer Giannis MountziosKostas N. Syrigos Review Article 21 November 2012 Pages: 175 - 186
Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? John-Joseph BorgGeorge AislaitnerStephen Mifsud Review Article 21 November 2012 Pages: 187 - 197
Safety of Nortriptyline at Equivalent Therapeutic Doses for Smoking Cessation Teerapon DhippayomNathorn ChaiyakunaprukThitima Jongchansittho Original Research Article 21 November 2012 Pages: 199 - 210
Parental Reporting of Adverse Drug Reactions Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Medications in Children Attending Specialist Paediatric Clinics in the UK Mansour TobaiqyDerek StewartJames McLay Original Research Article 21 November 2012 Pages: 211 - 219
Intensive Monitoring of Pregabalin Linda HärmarkEugène van PuijenbroekKees van Grootheest Original Research Article 21 November 2012 Pages: 221 - 231
A Computerized Adverse Drug Event Alerting System Using Clinical Rules Mirjam K. RommersIrene M. Teepe-TwissHenk-Jan Guchelaar Original Research Article 21 November 2012 Pages: 233 - 242
Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) Paul B. WatkinsMehul DesaiWillis Maddrey Original Research Article 21 November 2012 Pages: 243 - 252
Reporting Patterns Indicative of Adverse Drug Interactions Johanna StrandellOla CasterI. Ralph Edwards Original Research Article 21 November 2012 Pages: 253 - 266